• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer.

作者信息

Shaurova Tatiana, Yan Lingyue, Su Yafei, Rich Laurie James, Vincent-Chong Vui King, Calkins Hannah, Pokharel Saraswati, Petkovich Martin, Seshadri Mukund, Wu Yun, Hershberger Pamela Anne

机构信息

Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Department of Biomedical Engineering, University at Buffalo, the State University of New York, Buffalo, New York, USA.

出版信息

Cancer Commun (Lond). 2023 Apr;43(4):503-507. doi: 10.1002/cac2.12401. Epub 2023 Jan 24.

DOI:10.1002/cac2.12401
PMID:36691995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10091104/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da1/10091104/bbc5a4823b1e/CAC2-43-503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da1/10091104/bbc5a4823b1e/CAC2-43-503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da1/10091104/bbc5a4823b1e/CAC2-43-503-g001.jpg

相似文献

1
A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer.一种靶向肺癌中耐药细胞并克服表皮生长因子受体（EGFR）酪氨酸激酶抑制剂耐药性的纳米治疗策略。
Cancer Commun (Lond). 2023 Apr;43(4):503-507. doi: 10.1002/cac2.12401. Epub 2023 Jan 24.
2
Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.表皮生长因子受体酪氨酸激酶抑制剂治疗后的耐药性持久细胞：其起源及肿瘤微环境的影响
J Thorac Oncol. 2023 Apr;18(4):399-401. doi: 10.1016/j.jtho.2022.12.010.
3
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
4
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.蛋白酪氨酸激酶 2：克服非小细胞肺癌获得性 EGFR-TKI 耐药的新治疗靶点。
Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.
5
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.CDK7 抑制剂对非小细胞肺癌细胞系中 EMT 相关的第三代 EGFR-TKIs 耐药性的疗效。
Cells. 2020 Dec 3;9(12):2596. doi: 10.3390/cells9122596.
6
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.第二代表皮生长因子酪氨酸激酶抑制剂在非小细胞肺癌中的应用
Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843.
7
Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in -Mutated NSCLC.解析肿瘤内异质性对 EGFR 酪氨酸激酶抑制剂耐药的影响：-突变型 NSCLC 研究
Int J Mol Sci. 2023 Feb 18;24(4):4126. doi: 10.3390/ijms24044126.
8
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.克服非小细胞肺癌中 EGFR TKI 获得性耐药的策略。
Clin Transl Oncol. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Epub 2019 Mar 12.
9
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.非小细胞肺癌中 MET 酪氨酸激酶结构域的突变与酪氨酸激酶抑制剂耐药性。
Respir Res. 2023 Jan 25;24(1):28. doi: 10.1186/s12931-023-02329-1.
10
Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.增强表皮生长因子受体酪氨酸激酶抑制剂的癌症治疗的最新进展。
Mol Pharm. 2023 Feb 6;20(2):829-852. doi: 10.1021/acs.molpharmaceut.2c00792. Epub 2023 Jan 1.

引用本文的文献

1
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
2
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.来自 II 期研究的恩沙替尼治疗克唑替尼耐药 ALK 阳性 NSCLC 的更新总生存和循环肿瘤 DNA 分析。
Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29.

本文引用的文献

1
Overcoming therapy resistance in EGFR-mutant lung cancer.克服 EGFR 突变型肺癌的治疗抵抗。
Nat Cancer. 2021 Apr;2(4):377-391. doi: 10.1038/s43018-021-00195-8. Epub 2021 Apr 15.
2
Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.维生素D3代谢产物在KRAS突变型肺腺癌中显示出预后价值，并可用于对抗获得性治疗耐药性。
Cancers (Basel). 2020 Mar 13;12(3):675. doi: 10.3390/cancers12030675.
3
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
AXL 赋予了对奥希替尼的内在耐药性，并促进了耐药细胞的出现。
Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0.
4
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
5
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.多种耐药机制可能源于耐药性癌症持久细胞。
Nat Commun. 2016 Feb 19;7:10690. doi: 10.1038/ncomms10690.
6
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.肿瘤细胞可以沿着不同的进化路径对表皮生长因子受体抑制产生抗性。
Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.
7
Targeting Axl with an high-affinity inhibitory aptamer.用高亲和力抑制性适体靶向 Axl。
Mol Ther. 2012 Dec;20(12):2291-303. doi: 10.1038/mt.2012.163. Epub 2012 Aug 21.
8
CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.CYP24 抑制可保留肺癌细胞中 1α,25-二羟维生素 D(3) 的抗增殖信号。
Mol Cell Endocrinol. 2012 May 15;355(1):153-61. doi: 10.1016/j.mce.2012.02.006. Epub 2012 Feb 22.
9
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
10
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.肿瘤细胞亚群中染色质介导的可逆药物耐受状态。
Cell. 2010 Apr 2;141(1):69-80. doi: 10.1016/j.cell.2010.02.027.